Skip to content

The effectiveness of the standard four-drug regimen of Helicobacter pylori treatment containing pantoprazole or esomeprazole

Comparison the effectiveness of the standard four-drug regimen of Helicobacter pylori treatment containing pantoprazole or esomeprazole

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251129068149N1
Enrollment
110
Registered
2026-01-06
Start date
2026-01-20
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection associated with gastritis and indigestion. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: First intervention group: Standard quadruple bismuth treatment containing pantoprazole: Pantoprazole tablets 40 mg twice a day , Tetracycline capsules 500 mg four times a day ,Metronid

Sponsors

Shahre-kord University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Helicobacter pylori positive Over 18 years old Informed consent to participate in the study

Exclusion criteria

Exclusion criteria: malignant neoplasms previous treatment for Helicobacter pylori eradication

Design outcomes

Primary

MeasureTime frame
Helicobacter pylori eradication rate. Timepoint: 4 weeks after intervention. Method of measurement: Stool antigen test.;Percentage of response to treatment based on symptoms of the disease (pain, bloating, loss of appetite, heartburn). Timepoint: Before and after the intervention. Method of measurement: Patient history.

Secondary

MeasureTime frame
Percentage of treatment adherence. Timepoint: After the first and second weeks of intervention. Method of measurement: Researcher-made form for daily recording of treatment adherence.;Percentage of complications resulting from drug treatment. Timepoint: After the first and second weeks of intervention. Method of measurement: Researcher-made Adverse Drug Reaction Reporting Form.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Raeisi

Shahre-kord University of Medical Sciences

raesi.ah@skums.ac.ir+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026